NAD+: Side Effects

Safety Notice#

The safety profile of NAD+ supplementation (IV and oral precursors) in humans has been assessed in limited clinical trials. Most safety data derive from short-term studies of oral NR and NMN. IV NAD+ safety data come primarily from open-label clinical observations and small pilot studies.

Documented Adverse Effects#

IV NAD+ administration

• Nausea and gastrointestinal symptoms are the most commonly reported adverse effects during IV NAD+ infusions, occurring in a substantial proportion of patients when infusion rates exceed individual tolerance. Most clinics titrate infusion rate based on patient tolerance.
• Flushing, warmth, and skin redness are frequently reported and are typically rate-dependent, resolving when the infusion is slowed.
• Headache is commonly reported both during and after IV NAD+ sessions.
• Chest tightness and pressure have been reported at higher infusion rates; this typically resolves with rate reduction.
• Fatigue and muscle aches in the 24-48 hours following infusion have been reported anecdotally but are not well characterized in controlled studies.
• Serious adverse events with IV NAD+ have not been reported in published literature, though systematic safety monitoring in large controlled trials has not been conducted.

Oral NR (nicotinamide riboside)

• In randomized controlled trials, NR at doses up to 2000 mg/day for up to 12 weeks has been generally well tolerated.
• The most commonly reported side effects include mild gastrointestinal symptoms (nausea, diarrhea, abdominal discomfort).
• Some participants have reported flushing at higher doses, though NR causes substantially less flushing than nicotinic acid.
• Mild elevations in liver enzymes have been observed in some trials, typically within normal range; clinical significance is uncertain.
• Pruritus (itching) has been reported uncommonly.

Oral NMN (nicotinamide mononucleotide)

• NMN supplementation at doses up to 1250 mg/day has been tested in multiple human trials with generally favorable safety profiles.
• Adverse events are similar to NR and include mild GI symptoms.
• Limited long-term safety data beyond 12 weeks.

Summary table

Contraindications#

Active malignancy

• Cancer cells often upregulate NAD+ biosynthesis to support their high metabolic demands, enhanced DNA repair, and resistance to genotoxic therapies. Supplementing NAD+ could theoretically support cancer cell survival and resistance to chemotherapy or radiation.
• PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib) are FDA-approved cancer therapies that exploit NAD+ depletion at sites of DNA damage. Exogenous NAD+ supplementation could directly counteract their mechanism of action.
• Until more data are available, NAD+ supplementation should be avoided in patients with active malignancy, particularly those receiving PARP inhibitors or DNA-damaging chemotherapy.

Hepatic impairment

• The liver is a central organ for NAD+ metabolism, handling de novo synthesis from tryptophan, the Preiss-Handler pathway, and first-pass metabolism of oral precursors. Severe hepatic impairment may alter the metabolism and safety profile of NAD+ precursors.

Drug Interactions#

PARP inhibitors

• NAD+ is the direct substrate consumed by PARPs. Supplementing NAD+ during PARP inhibitor therapy could reduce the synthetic lethality mechanism that these drugs exploit in BRCA-mutant and homologous recombination-deficient cancers.

CD38-targeting therapies

• Daratumumab and related anti-CD38 antibodies used in multiple myeloma treatment target CD38, the dominant cellular NADase. Interactions between NAD+ supplementation and CD38-targeted therapies have not been studied but are theoretically possible.

Other NAD+ precursors and vitamin B3 forms

• Combining multiple NAD+ precursors (NR + NMN + niacin) could result in additive NAD+ loading and increased risk of hepatic effects or flushing, particularly with niacin.

Toxicology#

• No acute toxicity studies (LD50) specifically for NAD+ in standard laboratory animals have been widely reported in the literature.
• Oral NR has been granted Generally Recognized as Safe (GRAS) status by the FDA at doses up to 300 mg/day, with additional safety data supporting higher doses in clinical trials.
• NMN has been evaluated in toxicology studies in rodents without significant adverse findings at human-equivalent doses.
• Chronic toxicity data for IV NAD+ are absent; most clinical use is based on empirical experience rather than formal toxicology assessment.

Evidence Gaps#

• Systematic adverse event monitoring from large controlled trials of IV NAD+ has not been conducted
• Long-term safety data beyond 12 weeks are limited for all NAD+ augmentation strategies
• Drug interaction studies with chemotherapy agents, PARP inhibitors, and CD38 therapies have not been performed
• Safety in pregnancy and lactation has not been studied
• Dose-response relationship for adverse effects across different administration routes needs characterization

Related Reading#

• NAD+ overview and research guide
• NAD+ dosing protocols
• NAD+ risks and legal status